aldo-keto reductase family 1 member C2Genealiases: AKR1C-pseudo · BABP · DD · DD-2 · DD/BABP · DD2
Q-omics provides the consensus-scored AKR1C2 profile across patient tissues and cancer cell-line models. AKR1C2 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, AKR1C2 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, AKR1C2 protein abundance shows 17,505 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, KIRP, and GBM as cancer lineages where AKR1C2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKR1C2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKR1C2 survival associations across molecular data types. AKR1C2 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKR1C2 RNA expression–survival associations across cancer types. High AKR1C2 expression shows unfavorable associations in STAD, KIRP and HNSC, but favorable associations in KIRC, MESO and LGG. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for AKR1C2 RNA expression.
This table summarizes AKR1C2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for AKR1C2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKR1C2 shows lower tumor expression in THCA, KICH, COAD and BRCA and higher tumor expression in KIRP and HNSC. The KIRP box plot shows higher AKR1C2 RNA expression in tumor versus normal tissue (log2 FC = +3.291, t-test p < 0.001).
This table shows molecular features associated with AKR1C2 in patient tissues and cancer cell lines. In patient samples, AKR1C2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, AKR1C2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
